ADAMA Reports Third Quarter and First Nine Months 2025 Results

30 October 2025, Israel: ADAMA Ltd. (the “Company”) (SZSE 000553), today reported its financial results for the third quarter and first nine months of 2025 that ended September 30, 2025.

Third Quarter 2025 Highlights:

• Stable Sales (0% in USD, 1% in RMB) of $933 million, reflecting the combined results of a 1% increase in volume and a 1% decrease in prices
• Adjusted gross profit up 14% to $257 million, representing an improvement of gross margin to 27.6% from 24.2% last year, reflecting the benefits of lower costs and higher volumes
• Adjusted EBITDA up 50% to $120 million, representing an improvement of EBITDA margin to 12.9% from 8.6% last year
• Adjusted net loss reduced to $20 million from $78 million last year; Reported net loss improved by $85 million to $48 million compared to $133 million last year

First Nine Months 2025 Highlights:

• Stable Sales (0% in USD, 1% in RMB) of $3,025 million, reflecting the combined results of a 3% increase in volume and a 3% decrease in prices
• Adjusted gross profit up 12% to $878 million, representing an improvement of gross margin to 29.0% from 25.8% last year, reflecting the benefits of lower costs and higher volumes
• Adjusted EBITDA up 30% to $430 million, representing an improvement of EBITDA margin to 14.2% from 11.0% last year
• Adjusted net income turned positive to $29 million compared to a loss of $149 million last year; Reported net loss improved by $200 million to $59 million compared to $259 million last year
• Operating cash flow of $331 million generated $402 million last year
• Free cash flow of $112 million vs. $179 million last year

Gaël Hili, President and CEO of ADAMA, said, “In the third quarter, we continued to deliver improved financial results with stable sales and our sixth consecutive quarter of year-over-year EBITDA growth, clear indicators that our Fight Forward transformation plan is delivering results in support of our value innovation strategy. We remain focused on strengthening our operational foundations, enhancing commercial execution, and driving innovation across our portfolio, delivering meaningful impact for farmers and positioning ADAMA for sustainable, long-term profitable growth.”

Table 1. Financial Performance Summary

USD (m)	As Reported			Adjustments			Adjusted
	Q32025	Q32024	% Change		Q32025	Q32024	Q32025	Q32024	% Change
Revenues	933	929	0%		–	–	933	929	0%
Gross profit	236	188	25%		22	37	257	225	14%
% of sales	25.2%	20.2%					27.6%	24.2%
Operating income (loss) (EBIT)	30	(34)			26	46	56	13	343%
% of sales	3.2%	(3.6%)					6.0%	1.4%
Loss before taxes	(41)	(122)	67%		29	51	(11)	(72)	84%
% of sales	(4.4%)	(13.2%)					(1.2%)	(7.7%)
Net loss	(48)	(133)	64%		28	55	(20)	(78)	74%
% of sales	(5.1%)	(14.3%)					(2.1%)	(8.4%)
EPS
– USD	(0.0206)	(0.0569)					(0.0086)	(0.0335)
– RMB	(0.1470)	(0.4049)					(0.0611)	(0.2382)
EBITDA	104	56	87%		16	24	120	80	50%
% of sales	11.2%	6.0%					12.9%	8.6%

USD (m)	As Reported			Adjustments			Adjusted
	9M2025	9M2024	% Change		9M2025	9M2024	9M2025	9M2024	% Change
Revenues	3,025	3,028	0%		–	–	3,025	3,028	0%
Gross profit	792	672	18%		86	110	878	782	12%
% of sales	26.2%	22.2%					29.0%	25.8%
Operating income (EBIT)	155	1			81	136	237	137	73%
% of sales	5.1%	0.0%					7.8%	4.5%
Income (loss) before taxes	(58)	(203)	71%		91	116	33	(87)
% of sales	(1.9%)	(6.7%)					1.1%	(2.9%)
Net income (loss)	(59)	(259)	77%		89	110	29	(149)
% of sales	(2.0%)	(8.5%)					1.0%	(4.9%)
EPS
– USD	(0.0254)	(0.1110)					0.0127	(0.0638)
– RMB	(0.1815)	(0.7890)					0.0910	(0.4535)
EBITDA	378	252	50%		53	80	430	332	30%
% of sales	12.5%	8.3%					14.2%	11.0%

Relevant income statement items contained in this release are also presented on an “Adjusted” basis, which exclude items that are of a transitory or non-cash/non-operational nature that do not impact the ongoing performance of the business and reflect the way the Company’s management and the Board of Directors view the performance of the Company internally. The Company believes that excluding the effects of these items from its operating results allows management and investors to effectively compare the true underlying financial performance of its business from period to period and against its global peers. A detailed summary of these adjustments appears in the appendix below.

The number of shares used to calculate both basic and diluted earnings per share in both Q3 and 9M 2025 and 2024 is 2,329.8 million shares.

In this table and all tables in this release numbers may not sum due to rounding.

The General Crop Protection (CP) Market Environment

Through the first nine months of 2025, channel inventory returned to pre-pandemic levels in most countries, allowing crop protection demand recovery. Pricing pressure remains high, driven by production over-capacity of active ingredients. Crop commodity prices remain stably low and coupled with the high-interest rate environment, farmer profitability remains tight leading to just-in-time purchasing patterns.[1]

Portfolio Development Update

In the third quarter 2025, ADAMA continued to register and launch multiple new products in markets across the globe, adding on to its differentiated product portfolio. As part of the Fight Forward transformation plan, the Company is focused on improving its overall portfolio mix, particularly by targeting the Value Innovation segment, with the intent of improving value delivered to all stakeholders.

In Q3 2025, launches of differentiated products included: 

• FERRABAIT^®, a patented molluscicide composition based on the active ingredient FERALLA^®, has been launched in New Zealand for use in arable, horticultural, and ornamental crops.
• COSAYR^®, a long-lasting Chlorantraniliprole-based suspension, has been launched in Canada, Hungary, and Argentina (as CARTADO^®), to deliver fast and effective control of chewing insects across a wide range of horticultural and field crops.

Notable differentiated product registrations during Q3 2025 included:

• PORAFAM^®, an herbicide aqueous solution with Aminopyralid as the active ingredient, has been registered in Germany. This marks ADAMA’s first registration of an Aminopyralid-based formulation in Europe.
• The active substance FERALLA^® was registered UK
• COSAYR^® was registered in Austria, France, Spain and Greece
• AVASTEL^® a broad-spectrum fungicide utilizing Asorbital Formulation Technology and combining the active ingredients Prothioconazole and Fluxapyroxad, has been officially registered in Germany.
• EDAPTIS^® has been registered in Germany. This innovative post-emergence herbicide combines Pinoxaden and Mesosulfuron-methyl to provide effective control of a broad spectrum of grasses, including resistant populations, with a patented formulation that ensures stable and reliable performance.
• REXARO^® a fungicide suspension containing Cymoxanil and Fluopicolide, has been registered in Ghana.
• ETHOSAT^®, an herbicide suspension based on Ethofumesate active ingredient, has been registered in Finland. 

In addition, patents granted during Q3 2025 included GILBOA^® mixtures patents in multiple countries including Europe and US, and Gilboa formulation patents in the US and Columbia. Gilboa is a proprietary fungicide having a new mode of action for use in cereals. As well, BAROZ^™, a unique granular formulation for reliable rice stem borer control, was patented in Colombia and Indonesia.

Geopolitical Situation

ADAMA is headquartered and has three manufacturing sites in Israel. The regional tensions which escalated on October 7, 2023, continued to have no material impact to-date on the Company’s ability to support its markets or its consolidated financial results.

ADAMA is a global company with manufacturing and formulation facilities in several locations around the world, principally in Israel, China and Brazil. The Company’s management appointed a dedicated task force to analyze implications of US tariff policies and to closely monitor and manage the situation and the potential impact on its global network. Despite the uncertainty regarding the US tariff policies, the Company currently expects that the impact on its operations and business results will be immaterial.

‘Fight Forward’ Transformation Plan

In early 2024, ADAMA launched ‘Fight Forward’, a strategic transformation plan designed to deliver improved profit and cash targets over a three-year period. The plan optimizes financial management, streamlining ADAMA’s operating model in order to increase focus on the Value Innovation segment in which differentiated, high-impact solutions are developed to deliver greater value to farmers.

Financial Highlights

Revenues in the third quarter were stable (1% in RMB; 0% in CER) reaching $933 million, mainly reflecting the combined results of a 1% increase in volume and a 1% decrease in prices. The higher volumes reflected the gradual recovery of market demands and improvement of channel inventories in most regions. Prices remained weak mainly due to low prices of active ingredients in light of overcapacity, as well as a high interest rate ‎environment and low commodity prices, which put pressure on distributors and farmers.

Revenues in the first nine months were also stable (1% in RMB; 1% in CER) reaching $3,025 million. The stabilization of revenues in the first nine months was driven by volume growth of 3% offsetting a decrease in prices of 3%.

Table 2. Regional Sales Performance

		Q3 2025$m	Q3 2024$m	ChangeUSD	ChangeCER		9M 2025$m	9M 2024$m	ChangeUSD	ChangeCER
Europe, Africa & Middle East		233	216	8%	3%		903	911	(1%)	(2%)
North America		164	158	4%	4%		659	572	15%	16%
Latin America		312	287	9%	8%		675	687	(2%)	1%
Asia Pacific		225	269	(16%)	(15%)		789	859	(8%)	(7%)
Of which China		91	109	(17%)	(16%)		400	384	4%	4%
Total		933	929	0%	(0%)		3,025	3,028	(0%)	1%

Notes:

• CER: Constant Exchange Rates
• As part of ADAMA’s business optimization program, on January 1, 2025, ADAMA’s South Africa business was reclassified from APAC operations to EAME operations. To enable meaningful comparisons, the 2024 data presented here includes South Africa under EAME.
• Numbers may not sum due to rounding

Europe, Africa & Middle East (EAME): Volumes and revenue in EAME increased in the third quarter, though significant Q1 declines in Turkey impacted the year-to-date results. Pricing continued to decline in light of intense competition. Foreign exchange rates had positive impact in the third quarter.

North America: In the US Ag market, though slightly down in the third quarter, was significantly up in the first nine months following improvements in volumes and prices. Similarly in Canada, while the third quarter was flat with an increase in volume offset by a decrease by prices, for the nine months volumes are significantly up. Consumer & Professional Solutions experienced increased volumes and flat prices for both the third quarter and year-to-date.

Latin America: In Brazil, revenues were significantly up in the third quarter, resulting in higher revenues also for the first nine months compared to the previous year. Growth was driven by increased volumes, while the third quarter also experienced modest pricing increases. In the rest of LATAM lower volumes, prices, and revenues were reported in the third quarter and the first nine months, primarily in Paraguay and Argentina, due to channel destocking and just-in-time purchasing behavior.

Asia-Pacific (APAC): India experienced significant declines in the third quarter revenues, primarily due to lower volumes driven by extreme weather conditions and lower prices. In the rest of APAC (excluding India and China), sales and volumes were slightly up for the quarter, despite ongoing pricing pressures.

In China, sales in the third quarter mainly reflected the impacts of lower non-ag sales, partially compensated by the increase of AI sales. Non-ag sales declined following implementation of the company’s strategic decision to pivot away from manufacturing some basic chemical products, and weaker market demands. Higher AI sales were driven by volume growth due to the expansion of new distribution channels and supported by the recovery of global demand. Sales of the formulations business stabilized, still reflecting relatively high channel inventories and severe market competition. Supported by the growth in the first half, sales in China in the first nine months increased compared to last year.      

Reported gross profit in the third quarter increased 25% to $236 million (gross margin of 25.2%) from $188 million (gross margin of 20.2%) last year, and increased 18% to $792 million (gross margin of 26.2%) in the first nine months from $672 million (gross margin of 22.2%) last year.

Adjustments to reported results: The adjusted gross profit mainly includes reclassification of inventory impairment, taxes and surcharge, and excludes certain transportation costs (classified under operating expenses) and the remediation costs by a wholly owned subsidiary for its plant in Israel.

Adjusted gross profit in the third quarter increased 14% to $257 million (gross margin of 27.6%) from $225 million (gross margin of 24.2%) last year, and increased 12% to $878 million (gross margin of 29.0%) in the first nine months from $782 million (gross margin of 25.8%) last year.

The higher adjusted gross profit and margin in the quarter and first nine months mainly reflected the positive impacts of lower costs due to improved operational efficiency and lower costs of inventory sold as well as higher volume, more than compensating for lower prices.   

Operating expenses reported in the third quarter were $205 million (22.0% of sales), compared to $222 million (23.9% of sales) last year, and were $636 million (21.0% of sales) in the first nine months compared to $671 million (22.2% of sales) last year.

Adjustments to reported results: Please refer to the explanation above regarding adjustments to the gross profit in respect to certain transportation costs, taxes and surcharges and inventory impairment. Non-operating income and expenses are also reclassified into adjusted operating expenses.

The Company recorded certain non-operational items within its reported operating expenses amounting to $26 million in the third quarter of 2025 in comparison to $37 million in the third quarter of 2024 and $73 million in the first nine months 2025 in comparison to $113 million in the first nine months 2024. These items in 2025 mainly include: i. non-cash amortization charges in respect of transfer assets received from Syngenta related to the 2017 ChemChina-Syngenta acquisition; ii. non-cash amortization net charges related to intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions; and iii. restructuring and advisory costs incurred as part of the implementation of the Fight Forward transformation plan. For further details on these non-operational items, please see the appendix to this release.

Adjusted operating expenses in the third quarter were $201 million (21.5% of sales), compared to $212 million (22.8% of sales) last year, and were $641 million (21.2% of sales) in the first nine months compared to $645 million (21.3% of sales) last year.

The lower operating expenses in the third quarter was mainly due to a credit loss recorded last year, which compensated for an increase in expenses attributed to company success-based employee compensation due to improved 2025 results to-date. For the first nine months, the positive impacts following implementation of the Fight Forward plan more than compensated for expected credit losses due to liquidity issues of some local distributors in certain countries.

Reported operating income in the third quarter was $30 million (3.2% of sales) compared to a loss of $34 million (-3.6% of sales) last year, and increased to $155 million (5.1% of sales) in the first nine months from $1 million (0.0% of sales) last year.

Adjusted operating income in the third quarter increased to $56 million (6.0% of sales) from $13 million (1.4% of sales) last year, and increased to $237 million (7.8% of sales) in the first nine months from $137 million (4.5% of sales) last year. The increase in operating income was a combined result of higher gross profit and lower operating expenses.

Reported EBITDA in the third quarter increased to $104 million (11.2% of sales) from $56 million (6.0% of sales) last year, and increased to $378 million (12.5% of sales) in the first nine months from $252 million (8.3% of sales) last year.

Adjusted EBITDA in the third quarter increased to $120 million (12.9% of sales) from $80 million (8.6% of sales) last year, and increased to $430 million (14.2% of sales) in the first nine months from $332 million (11.0% of sales) last year.

Adjusted financial expenses decreased to $68 million in the third quarter compared to $84 million last year, and decreased to $204 million in the first nine months compared to $224 million last year.

The lower financial expenses in both the third quarter and the first nine months were primarily positively impacted by a bond buyback that was executed in late Q2, as well as the lower hedging costs related to the Israeli Shekel.

Adjusted taxes on income in the third quarter were an expense of $8 million, compared to expenses of $6 million in the corresponding period last year, and amounted to an expense of $4 million in the first nine months compared to expenses of $61 million last year.

The Company recorded tax expenses mainly ‎because losses that were primarily incurred by subsidiaries with relatively lower tax rates, while some ‎of them did not create deferred tax assets on the losses. On the other hand, the subsidiaries that ‎generated profit have a higher tax rate. ‎

The tax expenses in first nine months of 2025 are lower compared to the first nine months of 2024 due to (1) lower losses in subsidiaries that did not create deferred tax assets; (2) tax income raised by the accounting method of calculation of tax assets related to unrealized profits; and (3) foreign exchange impact of the stronger BRL in 2025 compared with tax expenses due to the weakness of the BRL in the first nine month of 2024.

Net loss reported in the third quarter narrowed to $48 million from $133 million last year, and narrowed to $59 million in the first nine months from $259 million last year.

After reflecting the impact of the aforementioned extraordinary and non-operational charges, adjusted net loss in the third quarter was reduced to $20 million from a loss of $78 million last year, and adjusted net income in the first nine months turned positive to $29 million from a loss of $149 million last year.

Trade working capital as of September 30, 2025, was $2,093 million compared to $2,218 million as of September 30, 2024. The decrease in working capital was mainly due to the decline in the level of inventory to $1,685 million as of September 30, 2025, from $1,740 million as of September 30, 2024. The decline of inventories was a result of continued implementation of enhanced inventory management, more than offsetting increased procurement in preparation to capture momentum as the market recovers, which also led to an increase in trade payables.

Cash Flow: Operating cash flow of $89 million and $331 million was generated in the third quarter and First Nine Months respectively, compared to $159 million and $402 million generated in the corresponding periods last year. The lower operating cash flow generated in the third quarter was mainly due to higher procurement payments in preparation to capture growth momentum. The dynamics in the first nine months reflected an improvement in collection offsetting higher outflow due to increased procurement payments.

Net cash used in investing activities was $43 million in the third quarter and $131 million in the First Nine Months, compared to $7 million and $122 million in the corresponding periods last year, respectively. The higher cash used in investing activities in the third quarter was mainly due to inflow from last year’s sale of a real estate asset. For the first nine months, the mild increase was also due to the payment for earn out related to AgriNova, a controlled subsidiary of the Company in Q2, more than offsetting prioritization of investments in manufacturing facilities and portfolio optimization.

Free cash flow of $22 million was generated in the third quarter and $112 million generated in the First Nine Months compared to $128 million and $179 million in the corresponding periods last year, respectively, reflecting the aforementioned operating and investing cash flow dynamics.

Table 3. Revenues by operating segment

Sales by segment

	Q3 2025USD (m)	%	Q3 2024USD (m)	%	9M 2025USD (m)	%	9M 2024USD (m)	%
Crop Protection	867	93%	840	90%	2,771	92%	2,746	91%
Intermediates and Ingredients	67	7%	89	10%	254	8%	282	9%
Total	933	100%	929	100%	3,025	100%	3,028	100%

Sales by product category

	Q3 2025USD (m)	%	Q3 2024USD (m)	%	9M 2025USD (m)	%	9M 2024USD (m)	%
Herbicides	369	40%	345	37%	1,288	43%	1,213	40%
Insecticides	311	33%	302	33%	857	28%	896	30%
Fungicides	187	20%	193	21%	626	21%	638	21%
Intermediates and Ingredients	67	7%	89	10%	254	8%	282	9%
Total	933	100%	929	100%	3,025	100%	3,028	100%

Notes:

The sales split by product category is provided for convenience purposes only and is not representative of the way the Company is managed or in which it makes its operational decisions.

Numbers may not sum due to rounding.

Also Read: DCM Shriram Acquires Four Salt Works to Boost Chemicals Business Supply Chain

📢 If You’re in Agriculture, Make Sure the Right People Hear Your Story.
From product launches to strategic announcements, Global Agriculture offers unmatched visibility across international agri-business markets. Connect with us at pr@global-agriculture.com to explore editorial and advertising opportunities that reach the right audience, worldwide.